Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluvoxamine + methylphenidate
- Development stage
- Phase 4
- Lead developer
- Abbott
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination involves fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) primarily used for treating obsessive-compulsive disorder (OCD), and methylphenidate, a central nervous system stimulant used to treat attention deficit hyperactivity disorder (ADHD). The combination has been studied for its potential in treating treatment-refractory OCD and ADHD with comorbid depression. Methylphenidate may increase fluvoxamine levels, potentially enhancing its effects but also increasing the risk of side effects[1][2].
02
Targets
DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on fluvoxamine + methylphenidate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluvoxamine + methylphenidate.